Evidence map›Paper›PMID 36233609›Full record

ArticleJournal of clinical medicine2022

Simple Application and Adherence to Gout Guidelines Enables Disease Control: An Observational Study in French Referral Centres.

Charlotte Jauffret, Sébastien Ottaviani, Augustin Latourte, Hang-Korng Ea, Sahara Graf, Frédéric Lioté, Thomas Bardin, Pascal Richette, Tristan Pascart

Abstract read
In one paragraph

Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Charlotte JauffretRheumatology Department, Saint-Philibert (GHICL), Lille Catholic University, 59160 Lille, France.ORCID 0000-0002-0973-5797
Sébastien OttavianiRheumatology Department, CHU Bichat (APHP), University Paris, 75018 Paris, France.
Augustin LatourteRheumatology Department, UMR 1132-Bioscar (Centre Viggo Petersen), CHU Lariboisière (APHP), University Paris, 75010 Paris, France.
Hang-Korng EaRheumatology Department, UMR 1132-Bioscar (Centre Viggo Petersen), CHU Lariboisière (APHP), University Paris, 75010 Paris, France.ORCID 0000-0002-2393-7475
Sahara GrafBiostatistics Department, Delegation for Clinical Research and Innovation, Lille Catholic University, 59160 Lille, France.
Frédéric LiotéRheumatology Department, UMR 1132-Bioscar (Centre Viggo Petersen), CHU Lariboisière (APHP), University Paris, 75010 Paris, France.ORCID 0000-0003-4419-0726
Thomas BardinRheumatology Department, UMR 1132-Bioscar (Centre Viggo Petersen), CHU Lariboisière (APHP), University Paris, 75010 Paris, France.
Pascal RichetteRheumatology Department, UMR 1132-Bioscar (Centre Viggo Petersen), CHU Lariboisière (APHP), University Paris, 75010 Paris, France.
Tristan PascartRheumatology Department, Saint-Philibert (GHICL), Lille Catholic University, 59160 Lille, France.ORCID 0000-0002-8395-826X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: In a context of therapeutic inertia, the French Society of Rheumatology (SFR) published its first recommendations on gout in 2020, which were deliberately simple and concise. The objectives of the study were to determine the profile of patients referred to French gout-expert centres, and to examine the results of their management and the factors leading to those results. Methods: Three hundred patients attending a first visit for gout management in three French referral centres were retrospectively and randomly included in this multicentre observational study. Visits were performed at baseline (M0) and scheduled for month 6 (M6), month 12 (M12), and month 24 (M24). Results: Patients were 81% male and had a mean age 62.2 ± 15.2 years. Management followed French recommendations after the baseline visit in 94.9% of cases. SU levels were below 6.0 mg/dL in 59.4% of patients at M6, 67.9% at M12, and 78.6% at M24, with increasing clinical improvement (i.e., flare decrease) over 2 years of follow-up. At M24, 50% of patients were treated with allopurinol (313 ± 105 mg/d), which exceeded renal restrictions of doses in 61.5% of them, and 48.2% received febuxostat (84 ± 36 mg/d). The need for a sufficient dosage of ULT was the only predictive factor found for successful achievement of SU levels < 6.0 mg/dL at a given visit. Conclusions: Simple application of gout-management guidelines is feasible in clinical practice and is efficient, with a majority of patients achieving SU targets and clinical improvement.

Indexed as

allopurinolanakinraclinical inertiafebuxostatgoutguidelinestreat-to-targeturate-lowering therapy

Identifiers

PMID36233609
PMCPMC9570816

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.